Based on sub-analysis of the prospective LUX-Lung 2, 3, and 6 trials22 (which included patients with uncommon mutations), the US Food and Drug Administration (FDA) and the European Medicines Agency approved afatinib for NSCLC patients with any sensitizing EGFR mutation (in addition to Del19 and L858R mutations).39 Few patients received first-line chemotherapy (mainly those with exon 20 insertions), but the median TTF of 6.6 months was shorter than that observed with EGFR TKIs. Here, EGFR is linked to non-small cell lung carcinoma.